Abstract
Lifetime prevalence of psychotic disorders varies widely across studies. Epidemiological surveys have rarely examined prevalences of specific psychotic disorders other than schizophrenia, and the majority used a single-phase design without employing clinical reappraisal interview for diagnostic verification. The current study investigated lifetime prevalence, correlates and service utilization of schizophrenia-spectrum, affective, and other non-affective psychotic disorders in a representative sample of community-dwelling Chinese adult population aged 16–75 years (N = 5719) based on a territory-wide, population-based household survey for mental disorders in Hong Kong. The survey adopted a 2-phase design comprising first-phase psychosis screening and second-phase diagnostic verification incorporating clinical information from psychiatrist-administered semi-structured interview and medical record review to ascertain DSM-IV lifetime diagnosis for psychotic disorders. Data on sociodemographics, psychosocial characteristics and service utilization were collected. Our results showed that lifetime prevalence was 2.47% for psychotic disorder overall, 1.25% for schizophrenia, 0.15% for delusional disorder, 0.38% for psychotic disorder not otherwise specified, 0.31% for bipolar disorder with psychosis, and 0.33% for depressive disorder with psychosis. Schizophrenia-spectrum disorder was associated with family history of psychosis, cigarette smoking and variables indicating socioeconomic disadvantage. Victimization experiences were significantly related to affective psychoses and other non-affective psychoses. Around 80% of participants with any psychotic disorder sought some kind of professional help for mental health problems in the past year. Using comprehensive diagnostic assessment involving interview and record data, our results indicate that approximately 2.5% of Chinese adult population had lifetime psychotic disorder which represents a major public health concern.
Keywords: epidemiology, population surveys, lifetime prevalence, schizophrenia, affective psychoses
Introduction
Psychotic disorders represent a group of severe mental disorders that constitutes one of the leading causes of disability worldwide.1 People with psychotic disorders experience significant functional impairment and are at markedly elevated risk of suicide,2 physical morbidity and premature mortality.3,4 The disorders incur substantial socioeconomic cost through direct healthcare spending and indirect costs such as loss of productivity and caregiver burden. They represent a major public health challenge, and are associated with a considerable degree of unmet therapeutic need.
Prevalence data are essential for disease burden estimation, service planning and aetiological investigation. Lifetime prevalence estimates of psychotic disorders vary widely across population-based surveys.5–7 Most previous research has focused on schizophrenia. Two recent reviews reported median lifetime prevalence of schizophrenia of 0.4% and 0.48%, respectively.6,7 A number of studies examined lifetime prevalence of more broadly-defined non-affective psychosis (NAP), with a range between 0.5% and 2.3%.8–14 Such divergence in prevalence rates may reflect true differences between geographic areas. It may also be attributable to methodological variation in survey design, sampling frame and strategy, as well as diagnostic procedures and criteria for case identification. In particular, prevalence estimates of psychosis in the community samples are strongly influenced by methods of assessment and diagnostic assignment. The majority of prior epidemiological surveys have adopted a single-phase design and relied on lay-administered fully-structured interviews to derive a diagnosis of psychotic disorders.6,7 Evidence has, nonetheless, demonstrated that diagnoses of psychotic disorders generated by lay-administered structured interviews are not well concordant with those ascertained by clinical reappraisal interviews conducted by psychiatrists.9,10,12 Very few population-based studies have used additional sources of information such as medical records to supplement interviews for diagnostic verification.12 Significant discrepancy in methodology and estimated prevalence precludes generalizability of findings to other communities. There is a paucity of data on prevalence of affective psychoses and specific psychotic disorders other than schizophrenia.
In this article, we present lifetime prevalences, sociodemographic and psychosocial correlates, and service utilization patterns of schizophrenia-spectrum, affective, and other non-affective psychotic disorders in a representative sample of the Chinese adult population in Hong Kong based on the Hong Kong Mental Morbidity Survey (HKMMS),15 which is the first territory-wide, population-based, face-to-face household survey for mental disorders in Hong Kong. The survey employed a 2-phase approach comprising first-phase psychosis screening and second-phase diagnostic verification incorporating clinical information from psychiatrist-administered semi-structured interview and medical record review so as to provide a more accurate estimation of lifetime prevalences of psychotic disorders.
Methods
Survey Design and Sample
The HKMMS is based on a representative, noninstitutionalized sample of the Hong Kong Chinese adult population. Hong Kong is a metropolitan city located at the southeastern tip of China. It has a population of approximately 7.24 million with ethnic Chinese comprising 91% of the population.16 The city covers an area of about 1100 km2 and is one of the most densely populated territories in the world (with average population density of 6690 persons/km2).
The survey adopted a multistage stratified cluster sampling procedure. The sampling frame consisted of randomly selected addresses provided by the Census and Statistics Department of Hong Kong Government, and were stratified according to geographical districts and the nature of premises (private/public housing). One adult aged 16–75 years was interviewed in each eligible household. This survey was restricted to community-dwelling adult population and did not examine people who were homeless, institutionalized (mental hospitals or residential homes) or in prison.
The study employed a 2-phase design, taking reference to the UK Adult Psychiatric Morbidity Survey.17,18 The phase 1 interview, which was administered by nonclinically trained research staff, comprised assessments on nonpsychotic mental disorders, alcohol and substance use, suicidal behaviors, and screening for possible psychosis. The interview also included questionnaires examining sociodemographics, health service utilization and risk factors for mental disorders. A total of 5719 respondents completed phase 1 interviews. The participation rate was 68%. A subsample of respondents (n = 312, 5.5% of the survey sample) who screened positive for psychosis in phase 1 were selected for a second phase aimed to provide a definitive ascertainment of psychotic disorder on the basis of clinician-administered diagnostic interview (Chinese-bilingual Structured Clinical Interview for DSM-IV, CB-SCID-I/P19) and medical record review. Two hundred thirty-two participants underwent second-phase diagnostic assessment (response rate: 74.4%). Of these, 94 (30.1%) were evaluated with both CB-SCID-I/P and medical record review, while 48 (15.4%) and 90 (28.8%) had only CB-SCID-I/P ratings and medical record data, respectively. To ascertain specificity of psychosis screen, 2% of the respondents (n = 110) who screened negative for psychosis in phase 1 were randomly selected to attend clinician-administered diagnostic interviews, with none having received lifetime diagnosis of any psychotic disorder (supplementary figure S1). Details of the survey method and findings regarding common mental disorders have been reported elsewhere.15,20 Fieldwork took place between November 2010 and May 2013. The study was approved by research ethics committees of the Chinese University of Hong Kong, the University of Hong Kong and the Hospital Authority. All participants provided written informed consent in each phase of the survey.
Identification of Psychotic Disorders
In phase 1, the Psychosis Screening Questionnaire (PSQ),21 which comprises 5 probes and 5 secondary questions enquiring about mania, thought interference, paranoia, strange experiences and hallucinations, was administered to screen for psychotic symptoms in the past 12 months. Supplementary enquiry for occurrence of these psychotic symptoms beyond the past year was also conducted to capture lifetime presence of possible psychosis. Respondents were invited for phase 2 assessment if they met one or more of the 5 following psychosis screening criteria: a self-reported diagnosis of psychotic disorder; past or current treatment with antipsychotic medication; a history of psychiatric inpatient treatment; endorsement of one or more of the 5 items in the PSQ; and endorsement of occurrence of psychotic symptoms in supplementary enquiry.
In phase 2, clinical diagnostic interviews and/or medical record reviews were conducted to verify lifetime diagnosis of psychotic disorder. The CB-SCID-I/P,19 a semi-structured interview providing DSM-IV22 diagnoses of psychotic disorders, was administered by qualified psychiatrists within 2 months following completion of the phase 1 assessment. A previous validation study showed that CB-SCID-I/P yielded reliable DSM-IV diagnoses in Chinese patients with psychotic disorders.19 Twenty-three psychiatrists, all with at least 5 years of clinical experience in treating mental disorders, conducted the diagnostic interviews. They completed intensive training on the use of CB-SCID-I/P and achieved satisfactory diagnostic concordance (κ = 0.75) prior to study commencement. All the CB-SCID-I/P ratings were reviewed by a senior research psychiatrist (L.L.C.W. or C.W.C.). Weekly research meetings were held throughout the study period to ensure strict adherence to the assessment protocol and to resolve discrepancies in diagnostic ratings between senior research psychiatrists and interviewers. In cases where clinical information was ambiguous, participants were re-contacted for clarification.
Participants’ medical records were retrieved from the computerized Clinical Management System (CMS)23 of the Hospital Authority for diagnostic verification, excluding those who refused consent to record review or had no prior contact with public healthcare system which is the major mental health service provider in Hong Kong for patients with severe mental disorder. The Hospital Authority manages all public hospitals, specialist and general outpatient clinics covering the whole territory of Hong Kong. The CMS is a centralized medical database comprising integrated, longitudinal electronic health records of all patients treated in public healthcare system across all service settings. Clinical information of CMS is directly recorded by clinicians and other healthcare professionals. In this study, medical notes were retrieved detailing inpatient, day-patient and outpatient psychiatric treatments, and prescription records of participants since their first contact with public mental health services. A clinical summary of each participant was compiled by a senior research staff member (W.C.S.M.), who systematically extracted cumulative lifetime clinical data from medical records using standardized data documentation form. The summary was scrutinized by a senior research psychiatrist (C.W.C.).
The final best-estimate lifetime DSM-IV diagnoses were determined by 2 senior research psychiatrists (L.L.C.W. and C.W.C.) in consensus diagnostic review meetings taking into consideration all available information including CB-SCID-I/P ratings and/or clinical summaries extracted from medical records. In this report, DSM-IV diagnoses for any psychotic disorder included schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, psychotic disorder not otherwise specified (NOS), bipolar disorder (BP) with psychotic features and major depressive disorder (MDD) with psychotic features. Substance-induced psychosis and psychotic disorder due to general medical condition were excluded.
Assessment of Correlates and Service Utilization
Sociodemographic assessments included age, sex, educational level, marital status, employment status, personal income and housing type. Data on family history of psychotic disorders and current smoking status were obtained. Alcohol consumption in the past year was assessed using Alcohol Use Disorders Identification Test24 with total score ≥8 indicating harmful drinking. A questionnaire was administered to obtain information on illicit substance use in the past year covering opiates, cannabis, ketamine, ecstasy, amphetamines, cocaine, tranquillizers, volatile substances, and hallucinogens. Lifetime exposure to potentially traumatic life events was evaluated using Life Event Checklist.25 To explore the relationship between victimization experience and psychosis, victimization was operationalized as the experience of any of the following lifetime traumatic life events: physical assault, assault with a weapon, sexual assault, other unwanted sexual experience or captivity. Information on health service utilization for mental health problems in the past year was also obtained.
Analytic Strategy
Lifetime prevalence estimates for psychotic disorders were computed by applying weightings in 2 steps. First, post-stratification weights were assigned on the basis of age, sex and housing type distributions using data from 2011 Hong Kong Population Census26 to assure the representativeness of the survey sample with respect to the total Hong Kong Chinese adult population. Second, weights were calculated as the inverse of the probability of response for nonresponse adjustment. Weighted prevalences were derived using a bootstrap resampling method, which generated SE from 1000 bootstrap replications with random replacement to account for the effects of stratification and clustering on variance estimates, and were presented as percentages with 95% CI, stratified by sex and age groups (16–30, 31–45, 46–60, and 61–75 years). Sex difference in prevalence of psychotic disorders was examined using chi-square test. To determine sociodemographic and psychosocial correlates of psychotic disorders, a series of univariate logistic regression analyses were conducted. Those variables that showed significant associations (P < .05) in preceding analyses were then included in multivariate regression models. ORs and 95% CIs were derived from regression models. Patterns of health service utilization in the past year were reported as proportions (%) with SE. Analyses of correlates and service utilization were conducted separately on the following broadly-defined diagnostic categories: any psychotic disorder, schizophrenia-spectrum disorder (schizophrenia, schizoaffective disorder and schizophreniform disorder), other non-affective psychoses (other NAP) (delusional disorder, brief psychotic disorder and psychotic disorder NOS), and affective psychoses (BP with psychotic features and MDD with psychotic features). The level of statistical significance was set at P < .05. All analyses were performed with STATA version 12.0 (StataCorp).
Results
Prevalence Estimates of Psychotic Disorders
Table 1 shows lifetime prevalence estimates of broadly-defined and specific diagnostic categories of psychotic disorders by sex. Lifetime prevalences of broadly-defined categories by sex and age groups are presented in table 2. Lifetime prevalence was 2.47% (95% CI: 1.99%–2.96%) for any psychotic disorder, 2.17% (95% CI: 1.39%–2.95%) for NAP (including schizophrenia-spectrum disorder and other NAP), 1.30% (95% CI: 0.94%–1.66%) for schizophrenia-spectrum disorder, 0.53% (95%CI: 0.33%–0.74%) for other NAP, and 0.64% (95% CI: 0.38%–0.90%) for affective psychoses. Of specific psychotic disorders, lifetime prevalence was highest for schizophrenia (1.25%, 95%CI: 0.90%–1.61%), followed by psychotic disorder NOS (0.38%, 95% CI: 0.20%–0.55%), MDD with psychotic features (0.33%, 95% CI: 0.14%–0.52%), BP with psychotic features (0.31%, 95% CI: 0.13%–0.50%), and delusional disorder (0.15%, 95% CI: 0.05%–0.26%). Only 1 and 3 participants received a lifetime diagnosis of schizophreniform disorder and schizoaffective disorder, respectively. None had brief psychotic disorder. There was no sex difference in lifetime prevalence of any broadly-defined and specific diagnostic categories of psychosis (all Ps > .05).
Table 1.
Lifetime Prevalences of DSM-IV Psychotic Disorders
Diagnosis | No. of Participantsa | Prevalence, % (95% CI)b,c | ||
---|---|---|---|---|
Men | Women | Total | ||
Any psychotic disorder | 130 | 2.12 (1.52–2.71) | 2.69 (2.00–3.37) | 2.47 (1.99–2.96) |
Non-affective psychosisd | 100 | 2.60 (0.76–4.43) | 1.91 (1.34–2.48) | 2.17 (1.39–2.95) |
Schizophrenia-spectrum disorder | 67 | 1.24 (0.78–1.70) | 1.34 (0.84–1.84) | 1.30 (0.94–1.66) |
Schizophrenia | 63 | 1.19 (0.74–1.65) | 1.29 (0.80–1.78) | 1.25 (0.90–1.61) |
Schizoaffective disordere | 3 | — | — | — |
Schizophreniform disorderf | 1 | — | — | — |
Other non-affective psychoses | 33 | 0.47 (0.20–0.74) | 0.57 (0.29–0.85) | 0.53 (0.33–0.74) |
Delusional disorder | 11 | 0.26 (0.05–0.47) | 0.09 (0.00–0.20) | 0.15 (0.05–0.26) |
Psychotic disorder NOS | 22 | 0.21 (0.03–0.39) | 0.48 (0.22–0.74) | 0.38 (0.20–0.55) |
Affective psychoses | 30 | 0.41 (0.14–0.68) | 0.78 (0.39–1.17) | 0.64 (0.38–0.90) |
BP with psychotic features | 15 | 0.26 (0.05–0.47) | 0.35 (0.08–0.61) | 0.31 (0.13–0.50) |
MDD with psychotic features | 15 | 0.15 (0.00–0.32) | 0.43 (0.14–0.72) | 0.33 (0.14–0.52) |
Note: BP, bipolar disorder; MDD, major depressive disorder; NOS, not otherwise specified.
aCrude number of psychotic disorder.
bWeighted prevalence estimates were computed to adjust the data to the 2011 Hong Kong Population Census on the basis of age, sex and housing type distributions, and for nonresponse in phase 2 assessment.
cThere was no significant sex difference in lifetime prevalence in each of the diagnostic categories for psychotic disorders (all Ps > .05).
dNon-affective psychosis included schizophrenia-spectrum disorder and other non-affective psychoses.
eOne man and 2 women were diagnosed to have schizoaffective disorder. Prevalence rates were not reported as the number of cases was too few to provide reliable estimates.
fOne man was diagnosed to have schizophreniform disorder. Prevalence rates were not reported as the number of cases was too few to provide reliable estimates.
Table 2.
Lifetime Prevalences of DSM-IV Psychotic Disorders by Age Groups and Sex
Prevalence by Age Group, % (95% CI)a | ||||
---|---|---|---|---|
Diagnosis | 16–30 Years | 31–45 Years | 46–60 Years | 61–75 Years |
All participants | ||||
Any psychotic disorder | 1.46 (0.61–2.32) | 2.64 (1.73–3.55) | 2.73 (1.90–3.57) | 2.49 (1.39–3.59) |
Non-affective psychosisb | 0.70 (0.14–1.26) | 2.05 (1.25–2.85) | 2.02 (1.32–2.71) | 2.13 (1.12–3.15) |
Schizophrenia-spectrum disorderc | 0.38 (0.00–0.78) | 1.68 (0.92–2.43) | 1.39 (0.80–1.98) | 1.17 (0.48–1.86) |
Other non-affective psychosesd | 0.32 (0.00–0.71) | 0.37 (0.09–0.66) | 0.62 (0.25–1.00) | 0.96 (0.21–1.71) |
Affective psychosese | 0.76 (0.11–1.41) | 0.59 (0.16–1.02) | 0.72 (0.24–1.20) | 0.36 (0.00–0.79) |
Men | ||||
Any psychotic disorder | 0.65 (0.01–1.29) | 3.30 (1.81–4.80) | 1.81 (0.95–2.67) | 2.44 (0.96–3.93) |
Non-affective psychosis | 0.46 (0.00–0.99) | 2.39 (1.10–3.68) | 1.66 (0.82–2.49) | 2.05 (0.77–3.34) |
Schizophrenia-spectrum disorder | 0.32 (0.00–0.78) | 1.65 (0.58–2.72) | 1.29 (0.55–2.03) | 1.42 (0.29–2.54) |
Other non-affective psychoses | 0.14 (0.00–0.41) | 0.74 (0.01–1.47) | 0.37 (0.00–0.74) | 0.64 (0.01–1.27) |
Affective psychoses | 0.19 (0.00–0.55) | 0.91 (0.14–1.68) | 0.16 (0.00–0.38) | 0.39 (0.00–1.15) |
Women | ||||
Any psychotic disorder | 2.06 (0.66–3.47) | 2.32 (1.19–3.46) | 3.28 (2.05–4.52) | 2.53 (0.94–4.11) |
Non-affective psychosis | 0.88 (0.00–1.76) | 1.89 (0.87–2.90) | 2.23 (1.24–3.22) | 2.19 (0.68–3.71) |
Schizophrenia-spectrum disorder | 0.42 (0.00–1.04) | 1.69 (0.70–2.68) | 1.45 (0.62–2.28) | 0.97 (0.11–1.84) |
Other non-affective psychoses | 0.45 (0.00–1.09) | 0.20 (0.00–0.43) | 0.78 (0.23–1.33) | 1.22 (0.01–2.48) |
Affective psychoses | 1.19 (0.09–2.29) | 0.44 (0.01–0.96) | 1.05 (0.30–1.81) | 0.33 (0.00–0.81) |
Note: NOS, not otherwise specified.
aWeighted prevalence estimates were computed to adjust the data to the 2011 Hong Kong Population Census on the basis of age, sex and housing type distributions, and for nonresponse in phase 2 assessment.
bNon-affective psychosis included schizophrenia-spectrum disorder and other non-affective psychoses.
cSchizophrenia-spectrum disorder included schizophrenia, schizoaffective disorder and schizophreniform disorder.
dOther non-affective psychoses included delusional disorder and psychotic disorder NOS.
eAffective psychoses included bipolar disorder with psychotic features and major depressive disorder with psychotic features.
Sociodemographic and Psychosocial Correlates of Psychotic Disorders
Supplementary table S1 and table 3 summarize the results on the associations of psychotic disorders with sociodemographic and psychosocial variables in univariate and multivariate analyses, respectively. Participants with any psychotic disorder were significantly more likely to be within the 3 older age strata (compared to the reference age group of 16–30 years), single or divorced/separated, unemployed, a current smoker, to have lower personal income (below HKD 6000 per month), a family history of psychotic disorder and experience of victimization. Schizophrenia-spectrum disorder was associated with the 3 older age groups, single or divorced/separated marital status, unemployment, low personal income, current smoker status and a family history of psychotic disorder. Being economically inactive was associated with a decreased odds ratio for schizophrenia-spectrum disorder. Other NAP was associated with substance use in the past year and victimization experience. Divorced/separated marital status, unemployment, a family history of psychotic disorder and victimization experience were associated with an increased probability of affective psychoses.
Table 3.
Sociodemographic and Psychosocial Correlates of Lifetime DSM-IV Psychotic Disorders in Multivariate Modelsa
Any Psychotic Disorder | SS Disorder | Other NAP | Affective Psychoses | |||||
---|---|---|---|---|---|---|---|---|
Variables | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P | OR (95% CI) | P |
Age | ||||||||
16–30 | Ref | Ref | — | — | ||||
31–45 | 4.92 (2.44–9.95) | <.001 *** | 9.70 (3.15–29.82) | <.001 *** | — | — | ||
46–60 | 3.67 (1.76–7.66) | .0 01 ** | 7.54 (2.35–24.14) | .001 ** | — | — | ||
61–75 | 3.22 (1.36–7.59) | .008 ** | 9.08 (2.39–34.48) | .001 ** | — | — | ||
Educational level | ||||||||
Primary level or below | Ref | Ref | Ref | — | ||||
Lower secondary level | 0.62 (0.35–1.12) | .117 | 0.52 (0.23–1.20) | .126 | 0.60 (0.23–1.55) | .294 | — | |
Upper secondary level | 0.70 (0.40–1.23) | .212 | 0.64 (0.29–1.38) | .251 | 0.38 (0.09–0.92) | .058 | — | |
Post-secondary level | 0.67 (0.29–1.56) | .353 | 0.62 (0.19–2.00) | .420 | 0.46 (0.10–2.09) | .315 | — | |
Marital status | ||||||||
Married or cohabited | Ref | Ref | Ref | Ref | ||||
Never married | 4.96 (2.97–8.26) | <.001 *** | 8.07 (4.01–16.27) | <.001 *** | 2.01 (0.76–5.36) | .162 | 2.52 (1.00–6.37) | .050 |
Divorced or separated | 2.62 (1.57–4.38) | <.001 *** | 2.48 (1.15–5.35) | .020 * | 2.09 (0.86–5.13) | .106 | 2.98 (1.13–7.87) | .028* |
Employment status | ||||||||
Working | Ref | Ref | Ref | Ref | ||||
Economically inactiveb | 0.58 (0.31–1.08) | .084 | 0.27 (0.10–0.74) | .010 * | 0.84 (0.29–2.37) | .737 | 0.83 (0.28–2.45) | .730 |
Unemployed | 3.02 (1.78–5.15) | <.001 *** | 2.63 (1.28–5.42) | .009 ** | 2.78 (0.99–7.79) | .052 | 3.00 (1.05–8.58) | .041 * |
Personal income per month (HKD)c | Ref | |||||||
Below 6,000 | Ref | Ref | Ref | Ref | ||||
6000–9999 | 0.54 (0.31–0.95) | .032 * | 0.29 (0.12–0.71) | .006 ** | 1.09 (0.43–2.78) | .848 | 0.83 (0.30–2.32) | .725 |
10 000–19 999 | 0.34 (0.17–0.66) | .001 ** | 0.28 (0.11–0.71) | .007 ** | 0.38 (0.09–1.53) | .172 | 0.51 (0.14–1.84) | .304 |
Above 20 000 | 0.07 (0.02–0.25) | <.001 *** | 0.03 (0.00–0.29) | .002 ** | 0.18 (0.02–1.74) | .139 | 0.15 (0.02–1.33) | .088 |
Type of housing | ||||||||
Private housing | Ref | Ref | Ref | Ref | ||||
Public housing | 1.34 (0.87–2.05) | .182 | 1.42 (0.78–2.59) | .257 | 1.13 (0.50–2.52) | .770 | 1.18 (0.54–2.62) | .675 |
Family history of psychotic disorder | ||||||||
No | Ref | Ref | — | Ref | ||||
Yes | 3.87 (2.01–7.44) | <.001 *** | 4.77 (2.12–10.75) | <.001 *** | — | 4.66 (1.55–14.00) | .006 ** | |
Current smoker | ||||||||
No | Ref | Ref | Ref | — | ||||
Yes | 1.65 (1.03–2.66) | .037 * | 2.19 (1.18–4.06) | .013 * | 1.38 (0.56–3.43) | .488 | — | |
Substance use in past year | ||||||||
No | Ref | — | Ref | — | ||||
Yes | 2.74 (0.78–9.67) | .116 | — | 7.13 (1.41–35.95) | .017 * | — | ||
Lifetime victimization experience | ||||||||
No | Ref | Ref | Ref | Ref | ||||
Yes | 2.15 (1.40–3.29) | <.001 *** | 1.22 (0.65–2.31) | .536 | 2.64 (1.20–5.81) | .016 * | 4.33 (2.03–9.22) | <.001*** |
Note: NAP, non-affective psychoses; SS, schizophrenia-spectrum.
aMultivariate regression analyses were conducted with adjusted odds ratios presented.
bEconomically inactive included retired, homemaker and student.
cPersonal income by quartile based on the 2011 Hong Kong Population Census; HKD 1 = USD 7.8.
*P < .05, **P < .01, ***P < .001.
Service Utilization
As shown in table 4, 79.8% of participants with any psychotic disorder had obtained some kind of professional help for mental health problems in the past year, and approximately 3-quarters had mental health specialty treatment (75.9%) and psychiatrist consultation (74.4%). Very few sought help from general medical health providers (2.3%) or traditional Chinese medical practitioners (0.8%), while 22.5% contacted social services. The proportion receiving any health service and mental health specialty treatment was significantly higher for schizophrenia-spectrum disorder and affective psychoses than for other NAP.
Table 4.
Twelve-month Health Service Utilization for Mental Health Problems in Participants with DSM-IV Psychotic Disorders
Types of Health Professionals | Any Psychotic Disorder (n = 130) | SS Disorder (n = 67) | Other NAP (n = 33) | Affective Psychoses (n = 30) | Group Differencesa |
---|---|---|---|---|---|
% (SE) | % (SE) | % (SE) | % (SE) | ||
Mental health specialty sector | 75.97 (3.78) | 86.57 (4.20) | 46.88 (8.96) | 83.33 (6.92) | SS > ONAP***, AP > ONAP** |
Psychiatrist | 74.42 (3.86) | 85.07 (4.39) | 43.75 (8.91) | 83.33 (6.92) | SS > ONAP***, AP > ONAP** |
Community psychiatric nurse | 6.98 (2.25) | 7.46 (3.23) | 6.67 (4.63) | 6.25 (4.35) | ns |
Occupational therapist | 4.65 (1.86) | 5.97 (2.92) | 0.00 | 6.67 (4.63) | ns |
Clinical psychologist | 7.75 (2.36) | 7.46 (3.23) | 9.38 (5.24) | 6.67 (4.63) | ns |
General medical sector | 2.33 (1.33) | 0.00 | 9.38 (5.24) | 0.00 | ONAP > SS* |
Primary care physician | 1.55 (1.09) | 0.00 | 6.25 (4.35) | 0.00 | ONAP > SS* |
Nonpsychiatrist specialist | 0.78 (0.78) | 0.00 | 3.13 (3.13) | 0.00 | ns |
Social worker | 22.48 (3.69) | 25.37 (5.36) | 15.63 (6.52) | 23.33 (7.85) | ns |
Traditional Chinese medicine | 0.78 (0.78) | 1.49 (1.49) | 0.00 | 0.00 | ns |
Any health service or treatment | 79.84 (3.55) | 86.57 (4.20) | 56.25 (8.91) | 90.00 (5.57) | SS > ONAP***, AP > ONAP** |
Note: AP, affective psychoses; ONAP, other non-affective psychoses; NAP, non-affective psychoses; ns, not significant; SS, schizophrenia-spectrum.
aChi-square tests were performed for group comparison.
*P < .05, **P < .01, ***P < .001.
Discussion
The HKMMS is one of the few epidemiological surveys reporting prevalence rates of specific psychotic disorders other than schizophrenia and broadly-defined categories of psychoses. The study is also among the very few general population studies which adopted a 2-phase design utilizing information from clinical reappraisal interview and medical records for diagnostic ascertainment. Our results showed that lifetime prevalence of any psychotic disorder in the Hong Kong Chinese adult population was approximately 2.5%. NAP (2.17%) was more common than affective psychoses (0.64%), and schizophrenia was the most prevalent specific psychotic disorder, with lifetime prevalence of 1.25%.
Methodological Limitations
Several methodological limitations should be considered prior to interpreting the study results. First, similar to many previous community-based epidemiological surveys, we did not include people who were homeless, incarcerated or institutionalized. As prevalence of psychosis in these excluded population segments is significantly higher than in the community,27–29 our results would likely underestimate lifetime rates of psychotic disorders in the entire Chinese adult population of Hong Kong. Second, nonparticipation in the survey might introduce bias in prevalence estimation. Nonetheless, the attrition effect was minimized by applying weighting procedure for nonresponse adjustment. Third, the cross-sectional study design precluded us from drawing conclusions about causal relationships between identified correlates and psychotic disorders. Fourth, although household sampling strategy enabled us to detect “untreated” cases of psychotic disorders in the community (vs studies examining “treated” populations identified through case-registers12 or sampled from more extended treatment facilities including public specialized psychiatric services, community centers providing care to mentally ills, private psychiatrists and general practitioners30,31), in the context of studying low-prevalence disorders like psychotic disorders, this method of case ascertainment might not yield adequate number of cases for more refined epidemiological and clinical analyses.32 Fifth, given the significant variations between Hong Kong and Mainland China regarding the degrees of urbanicity, population density and economic development, and socio-cultural profiles, our data might not be generalizable to the rest of China.
Lifetime Prevalence Estimates
Our prevalence rates of NAP and schizophrenia were comparatively higher than those in many previous population-based studies. However, these epidemiological surveys themselves demonstrated marked variations in lifetime prevalence of schizophrenia in different geographic areas, ranging between 0.12% and 1.9%.9,12,13,33–48 A meta-analytic review revealed an almost 8-fold cross-study difference in lifetime prevalence of schizophrenia.6 Results of the recently published World Health Survey (WHS) also showed considerable cross-country heterogeneity in lifetime prevalence (0.07%–5.7%) of schizophrenia.49 There is evidence suggesting that estimated prevalence varied with differences in economic status and degree of urbanicity of the regions studied. Some prior reports found that developed countries6 and urban areas9,14,43,48 yielded higher prevalence than developing countries and rural areas. Methodological variation also contributes to a large discrepancy in prevalence estimates. Evidence indicates that epidemiological surveys with higher study quality6,7 and using additional sources of information such as medical records or case-registers to supplement clinical reappraisal interviews for diagnostic assessment12,38 reported higher prevalence. Hong Kong is a highly urbanized, densely populated city and is categorized by the World Bank as a high-income economy.50 The specific geospatial and socioeconomic profiles of Hong Kong, alongside our wide age coverage (16–75 years) and more comprehensive diagnostic verification procedures incorporating semi-structured interview and medical record data might explain an increase in case detection and higher prevalence estimates. Of note, our findings of low prevalence rates in men aged 16–30 years, as compared to the other age groups, were unexpected and in contrast to the literature.32 These results, however, might partly be attributable to an underrepresentation of males and younger age groups in our survey sample (relative to the Hong Kong adult population) even though weighting procedure was applied to adjust for potential nonparticipation bias, and should be viewed with caution.
Very few general population studies have examined lifetime prevalence of specific psychotic disorders other than schizophrenia. Our results indicated that schizoaffective and schizophreniform disorders were rare in the community. No participant was diagnosed with brief psychotic disorder. Overall, our findings are broadly consistent with those few population-based surveys12,33,35,37,38,40,42,45 suggesting that these disorders were the least prevalent diagnoses among various specific psychotic disorders. Lifetime prevalence of delusional disorder also largely accords with the results of previous studies. An earlier review reported lifetime prevalence of delusional disorder ranging between 0.024% and 0.03%.51 More recent population-based surveys revealed lifetime estimates with a range from 0.048% to 0.18%.12,35 Nonetheless, prevalence of delusional disorder is likely to be an underestimate, as individuals with the disorder rarely seek treatment due both to a lack of insight and to relatively preserved functional capacity. The non-bizarre and circumscribed nature of delusions also makes delusional disorder difficult to diagnose accurately from a single semi-structured interview, particularly when no additional sources of information are available for verification.
We found that lifetime prevalence of BP with psychotic features was 0.31%. To our knowledge, there is only one previous general population survey (Psychoses in Finland Study) examining prevalence of BP with psychotic features, reporting a lifetime estimate of 0.12%.12 All other past population-based studies investigating prevalence of bipolar I disorder focused on an overall estimate comprising individuals with and without psychotic features. A recent review reported an aggregate cross-study lifetime prevalence of bipolar I disorder as 1.2% (range: 0.1%–3.3%).52 Our higher prevalence compared with the Finnish study might partly be due to our wider age coverage for survey sampling (16–75 years vs ≥30 years). Given that the onset of BP frequently occurs in young adulthood, exclusion of subjects aged below 30 years might underestimate prevalence by missing those cases with earlier age of illness onset. Our lifetime prevalence of MDD with psychotic features is close to the lower range (0.33%–0.6%) of those reported by the few prior population-based surveys.12,53,54
Correlates and Service Utilization
The findings that schizophrenia-spectrum disorder was associated with unemployment, low personal income, and single or divorce/separated marital status are in keeping with the literature, which indicates that individuals with schizophrenia are significantly more likely to be socioeconomically disadvantaged.55 People with a positive family history of psychosis were found to be significantly more likely to have schizophrenia-spectrum disorder or affective psychoses. Consistent with 2 systematic reviews5,6 and previous epidemiological surveys conducted in the Chinese populations of Hong Kong,40 Mainland China48 and Taiwan,35 we found no sex difference in prevalences of schizophrenia-spectrum disorder and other NAP. This is, however, discordant with the evidence indicating higher incidence of schizophrenia in men than women.56 One plausible explanation for such discrepancy is that males with schizophrenia and related psychoses have shorter lifespan than female counterparts. In fact, a recent meta-analysis on schizophrenia samples has revealed significantly lower average life expectancy for men than women.57 Accumulating evidence has further suggested than men have a higher mortality rate than women, particularly in the early course of illness.58 Conversely, our result of lack of sex difference in lifetime prevalence of MDD with psychotic features was unexpected and contrary to some previous studies demonstrating female preponderance in this disorder.53,54 This, however, should be interpreted with caution as accuracy in sex ratio estimation was likely compromised by small sample size (n = 15) of the disorder. Our finding that current smoking status was associated with an increased odds ratio to schizophrenia-spectrum disorder concurs with a substantial body of research demonstrating significantly higher prevalence of tobacco use in schizophrenia patients compared to the general population.59 Although there is emerging evidence that cigarette smoking may increase the risk for psychosis,60,61 the cross-sectional design of our study precluded us from examining the directionality of the associations between smoking and schizophrenia-spectrum disorder. Likewise, further clarification of the potential mechanisms (social drift vs social causation) underlying the associations between sociodemographic correlates and psychotic disorders could not be addressed by this study.
Our study revealed that substance use in the past year was significantly associated with other NAP, but not with schizophrenia-spectrum disorder or affective psychoses. This was at odds with most previous studies conducted in western countries which showed that schizophrenia patients had markedly higher rates of comorbid substance use than the general population.31,62 It is noteworthy that our very low 12-month prevalence of substance use (1.8%), possibly biased by under-reporting, may obscure the potential relationship between substance use and psychotic disorders. It should also be acknowledged that comorbid substance abuse is much less frequently observed in our psychosis samples compared to those in western populations. One previous study showed that only 5.6% of Chinese first-episode psychosis patients had concurrent substance use disorder.63 Victimization experiences have recently been identified as a putative risk factor for psychosis (in particular childhood adversity and trauma).64 Here, our findings of an association with psychotic disorders accords with the second UK Adult Psychiatric Morbidity Survey, in which people with psychosis were significantly more likely to experience victimizing events than the general population and those with other nonpsychotic mental disorders.65 Our results further suggested that victimization exposure might be more strongly related to affective psychoses than other broadly-defined psychoses. Nonetheless, our results on the associations between victimization and psychotic disorders should be interpreted with caution. First, assessment of victimization was based on retrospective self-reports which are subject to recall bias. Second, information about the timing of victimization exposure and onset of psychosis was not collected. Hence, we were not able to examine the temporal relationship between victimization and psychosis development. Furthermore, patients with established psychotic disorders are also found to be susceptible to victimization.66,67 Prospective investigation with refined measurement of victimization experience is warranted to clarify its impact on risk for psychosis.
Our findings that 3-quarters of participants with psychotic disorder reported specialist mental health treatment in the 12 months preceding interview is consistent with the literature which finds that the vast majority of people with psychosis are in contact with the health service system.68 A significantly greater proportion of participants (above 80%) with schizophrenia-spectrum disorder or affective psychoses visited mental health professionals than those with other NAP (less than 50%). This may probably reflect aspects of the illness in specific psychotic disorders of other NAP (eg, poor insight in delusional disorder and potentially milder illness severity of psychotic disorder NOS that evades early detection), resulting in lower rates of help-seeking behavior.
Conclusion
Our results indicate that approximately 2.5% of the Hong Kong Chinese adult population had a lifetime diagnosis of psychotic disorder, constituting a considerable burden to patients, families and society. This underscores an urgent need to improve the effectiveness of individual treatments and healthcare delivery systems in order to enhance early recovery from these severe mental disorders.
Supplementary Material
Supplementary data are available at Schizophrenia Bulletin online.
Funding
This study was supported by the Health and Health Services Research Fund (Ref: 09101601) of the Food and Health Bureau, the Government of Hong Kong Special Administrative Region.
Supplementary Material
Acknowledgments
We thank all the fieldwork investigators of the HKMMS. We are also grateful to the individuals who participated in the study. The authors declared no conflicts of interest regarding the subject of this study. HKMMS team investigators for diagnostic interview (in alphabetical order): Chario CC Chan1, LK Chan2, WC Chan3, WC Chang3, WH Cheung2, Patricia WY Choi2, Kavin KW Chow4, Paulina PL Chow4, Jackie CK Fu4, Karen SY Hung4, Condy HS Kwan2, Gary KW Lau5, Edwin HM Lee3, Allen TC Lee5, Grace TY Leung5, Joey SY Leung2, Bonnie WM Siu4, Winki WK Tai5, Victoria WK Tang4, CK Tung4, Candy HY Wong5, Amy SW Yeung4, and Zoe HS Yu2. 1Department of Psychiatry, Shatin Hospital; 2Department of Psychiatry, Kwai Chung Hospital; 3Department of Psychiatry, the University of Hong Kong; 4Department of Psychiatry, Castle Peak Hospital; 5Department of Psychiatry, Tai Po Hospital.
References
- 1. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry. 2005;62:247–253. [DOI] [PubMed] [Google Scholar]
- 3. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123–1131. [DOI] [PubMed] [Google Scholar]
- 4. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72:334–341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry. 2002;47:833–843. [DOI] [PubMed] [Google Scholar]
- 6. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005;2:e141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990–2013: a systematic literature review. BMC Psychiatry. 2015;15:193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8–19. [DOI] [PubMed] [Google Scholar]
- 9. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Arch Gen Psychiatry. 1996;53:1022–1031. [DOI] [PubMed] [Google Scholar]
- 10. Kessler RC, Birnbaum H, Demler O, et al. The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry. 2005;58:668–676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Vicente B, Kohn R, Rioseco P, Saldivia S, Levav I, Torres S. Lifetime and 12-month prevalence of DSM-III-R disorders in the Chile psychiatric prevalence study. Am J Psychiatry. 2006;163:1362–1370. [DOI] [PubMed] [Google Scholar]
- 12. Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry. 2007;64:19–28. [DOI] [PubMed] [Google Scholar]
- 13. Ochoa S, Haro JM, Torres JV, et al. What is the relative importance of self reported psychotic symptoms in epidemiological studies? Results from the ESEMeD–Catalonia Study. Schizophr Res. 2008;102:261–269. [DOI] [PubMed] [Google Scholar]
- 14. Gureje O, Olowosegun O, Adebayo K, Stein DJ. The prevalence and profile of non-affective psychosis in the Nigerian Survey of Mental Health and Wellbeing. World Psychiatry. 2010;9:50–55. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Lam LCW, Chan WC, Wong CSM, et al. The Hong Kong mental morbidity survey: background and study design. East Asian Arch Psychiatry. 2014;24:30–36. [PubMed] [Google Scholar]
- 16. Hong Kong Census and Statistics Department. Hong Kong Annual Digest of Statistics 2015 Edition. Hong Kong Special Administrative Region: Census and Statistics Department; 2015. [Google Scholar]
- 17. Jenkins R, Bebbington P, Brugha T, et al. The National psychiatric morbidity surveys of Great Britain–strategy and methods. Psychol Med. 1997;27:765–774. [DOI] [PubMed] [Google Scholar]
- 18. Jenkins R, Meltzer H, Bebbington P, et al. The British Mental Health Survey Programme: achievements and latest findings. Soc Psychiatry Psychiatr Epidemiol. 2009;44:899–904. [DOI] [PubMed] [Google Scholar]
- 19. Lam LCW, Wong CSM, Wang MJ, et al. Prevalence, psychosocial correlates and service utilization of depressive and anxiety disorders in Hong Kong: the Hong Kong Mental Morbidity Survey (HKMMS). Soc Psychiatry Psychiatr Epidemiol. 2015;50:1379–1388. [DOI] [PubMed] [Google Scholar]
- 20. Bebbington P, Nayani T. The Psychosis Screening Questionnaire. Int J Methods Psychiatr Res 1995;5:11–19. [Google Scholar]
- 21. So E, Kam I, Leung CM, Chung D, Liu Z, Fong S. The Chinese-bilingual SCID-I/P project: stage 1-reliability for mood disorders and schizophrenia. Hong Kong J Psychiatry. 2003;13:7–18. [Google Scholar]
- 22. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition, Revised) (DSM-IV-TR).Washington, DC: American Psychiatric Association; 2000. [Google Scholar]
- 23. Cheung NT, Fung V, Wong WN, et al. Principles-based medical informatics for success–how Hong Kong built one of the world’s largest integrated longitudinal electronic patient records. Stud Health Technol Inform. 2007;129:307–310. [PubMed] [Google Scholar]
- 24. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption–II. Addiction. 1993;88:791–804. [DOI] [PubMed] [Google Scholar]
- 25. Gray MJ, Litz BT, Hsu JL, Lombardo TW. Psychometric properties of the life events checklist. Assessment. 2004;11:330–341. [DOI] [PubMed] [Google Scholar]
- 26. Hong Kong Census Statistics Department. Demographic Trends in Hong Kong 1981–2011. Hong Kong Special Administrative Region: Census and Statistics Department; 2012. [Google Scholar]
- 27. Fazel S, Danesh J. Serious mental disorder in 23000 prisoners: a systematic review of 62 surveys. Lancet. 2002;359:545–550. [DOI] [PubMed] [Google Scholar]
- 28. Brugha T, Singleton N, Meltzer H, et al. Psychosis in the community and in prisons: a report from the British National Survey of psychiatric morbidity. Am J Psychiatry. 2005;162:774–780. [DOI] [PubMed] [Google Scholar]
- 29. Yim LCL, Leung HCM, Chan WC, Lam MHB, Lim VWM. Prevalence of Mental Illness among Homeless People in Hong Kong. PLoS One. 2015;10:e0140940. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Jablensky A, McGrath J, Herrman H, et al. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. Aust N Z J Psychiatry. 2000;34:221–236. [DOI] [PubMed] [Google Scholar]
- 31. Morgan VA, McGrath JJ, Jablensky A, et al. Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychol Med. 2014;44:2163–2176. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Jablensky A, Kirkbride JB, Jones PB. Schizophrenia: the epidemiological horizon. In: Weinberger DR, Harrison PJ, eds. Schizophrenia. 3rd ed. Chichester, West Sussex, UK: Blackwell Publishing Ltd; 2011:185–225. [Google Scholar]
- 33. Canino GJ, Bird HR, Shrout PE, et al. The prevalence of specific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry. 1987;44:727–735. [DOI] [PubMed] [Google Scholar]
- 34. Oakley-Browne MA, Joyce PR, Wells JE, Bushnell JA, Hornblow AR. Christchurch psychiatric epidemiology study, part II: six month and other period prevalences of specific psychiatric disorders. Aust N Z J Psychiatry. 1989;23:327–340. [DOI] [PubMed] [Google Scholar]
- 35. Hwu HG, Yeh EK, Chang LY. Prevalence of psychiatric disorders in Taiwan defined by the Chinese diagnostic interview schedule. Acta Psychiatr Scand. 1989;79:136–147. [DOI] [PubMed] [Google Scholar]
- 36. Lee CK, Kwak YS, Yamamoto J, et al. Psychiatric epidemiology in Korea. Part I: Gender and age differences in Seoul. J Nerv Ment Dis. 1990;178:242–246. [DOI] [PubMed] [Google Scholar]
- 37. Keith SJ, Regier DA, Rae DS. Schizophrenic disorders. In: Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: Free Press; 1991:33–52. [Google Scholar]
- 38. Lehtinen V, Joukamaa M, Jyrkinen T, et al. Mental health and mental disorders in the Finnish adult population.Turku and Helsinki, Finland: Publications of the Social Insurance Institution; 1991. [Google Scholar]
- 39. Wittchen HU, Essau CA, von Zerssen D, Krieg JC, Zaudig M. Lifetime and six-month prevalence of mental disorders in the Munich Follow-Up Study. Eur Arch Psychiatry Clin Neurosci. 1992;241:247–258. [DOI] [PubMed] [Google Scholar]
- 40. Chen CN, Wong J, Lee N, Chan-Ho MW, Lau JT, Fung M. The Shatin community mental health survey in Hong Kong. II. Major findings. Arch Gen Psychiatry. 1993;50:125–133. [DOI] [PubMed] [Google Scholar]
- 41. Kebede D, Alem A, Shibre T, et al. Onset and clinical course of schizophrenia in Butajira-Ethiopia–a community-based study. Soc Psychiatry Psychiatr Epidemiol. 2003;38:625–631. [DOI] [PubMed] [Google Scholar]
- 42. Kebede D, Alem A. Major mental disorders in Addis Ababa, Ethiopia. I. Schizophrenia, schizoaffective and cognitive disorders. Acta Psychiatr Scand Suppl. 1999;397:11–17. [DOI] [PubMed] [Google Scholar]
- 43. van Os J, Hanssen M, Bijl RV, Vollebergh W. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry. 2001;58:663–668. [DOI] [PubMed] [Google Scholar]
- 44. Ran MS, Xiang MZ, Li SX, et al. Prevalence and course of schizophrenia in a Chinese rural area. Aust N Z J Psychiatry. 2003;37:452–457. [DOI] [PubMed] [Google Scholar]
- 45. Cho MJ, Kim JK, Jeon HJ, et al. Lifetime and 12-month prevalence of DSM-IV psychiatric disorders among Korean adults. J Nerv Ment Dis. 2007;195:203–210. [DOI] [PubMed] [Google Scholar]
- 46. Xiang YT, Ma X, Cai ZJ, et al. Prevalence and socio-demographic correlates of schizophrenia in Beijing, China. Schizophr Res. 2008;102:270–277. [DOI] [PubMed] [Google Scholar]
- 47. Cho MJ, Chang SM, Lee YM, et al. Prevalence of DSM-IV major mental disorders among Korean adults: A 2006 National Epidemiologic Survey (KECA-R). Asian J Psychiatr. 2010;3:26–30. [DOI] [PubMed] [Google Scholar]
- 48. Long J, Huang G, Liang W, et al. The prevalence of schizophrenia in mainland China: evidence from epidemiological surveys. Acta Psychiatr Scand. 2014;130:244–256. [DOI] [PubMed] [Google Scholar]
- 49. Nuevo R, Chatterji S, Verdes E, Naidoo N, Arango C, Ayuso-Mateos JL. The continuum of psychotic symptoms in the general population: a cross-national study. Schizophr Bull. 2012;38:475–485. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. World Bank. World Bank List of Economies 2011. http://data.worldbank.org/about/country-classifications/country-and-lending-groups Accessed August 7, 2016.
- 51. Kendler KS. Demography of paranoid psychosis (delusional disorder): a review and comparison with schizophrenia and affective illness. Arch Gen Psychiatry. 1982;39:890–902. [DOI] [PubMed] [Google Scholar]
- 52. Merikangas KR, Pato M. Recent developments in the epidemiology of bipolar disorder in adults and children: magnitude, correlates, and future directions. Clin Psychol Sci Pract. 2009;16:121–133. [Google Scholar]
- 53. Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry. 1991;48:1075–1081. [DOI] [PubMed] [Google Scholar]
- 54. Ohayon MM, Schatzberg AF. Prevalence of depressive episodes with psychotic features in the general population. Am J Psychiatry. 2002;159:1855–1861. [DOI] [PubMed] [Google Scholar]
- 55. Jablensky A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur Arch Psychiatry Clin Neurosci. 2000;250:274–285. [DOI] [PubMed] [Google Scholar]
- 56. McGrath J, Saha S, Welham J, et al. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004;2:13. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Hjorthoj C, Sturup AE, McGrath JJ, Nordentoft M. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis [published online ahead of print February 22, 2017]. Lancet Psychiatry. doi:10.1016/S2215-0366(17)30078-0. [DOI] [PubMed] [Google Scholar]
- 58. Reininghaus U, Dutta R, Dazzan P, et al. Mortality in schizophrenia and other psychoses: a 10-year follow-up of the ӔSOP first-episode cohort. Schizophr Bull. 2015;41:664–673. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135–157. [DOI] [PubMed] [Google Scholar]
- 60. Kendler KS, Lönn SL, Sundquist J, Sundquist K. Smoking and schizophrenia in population cohorts of Swedish women and men: a prospective co-relative control study. Am J Psychiatry. 2015;172:1092–1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61. Gurillo P, Jauhar S, Murray RM, MacCabe JH. Does tobacco use cause psychosis? Systematic review and meta-analysis. Lancet Psychiatry. 2015;2:718–725. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014;71:248–254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Chang WC, Chan SS, Hui CL, Chan SK, Lee EH, Chen EY. Prevalence and risk factors for violent behavior in young people presenting with first-episode psychosis in Hong Kong: A 3-year follow-up study. Aust N Z J Psychiatry. 2015;49:914–922. [DOI] [PubMed] [Google Scholar]
- 64. Varese F, Smeets F, Drukker M, et al. Childhood adversities increase the risk of psychosis: a meta-analysis of patient-control, prospective- and cross-sectional cohort studies. Schizophr Bull. 2012;38:661–671. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65. Bebbington PE, Bhugra D, Brugha T, et al. Psychosis, victimisation and childhood disadvantage: evidence from the second British National Survey of Psychiatric Morbidity. Br J Psychiatry. 2004;185:220–226. [DOI] [PubMed] [Google Scholar]
- 66. Khalifeh H, Johnson S, Howard LM, et al. Violent and non-violent crime against adults with severe mental illness. Br J Psychiatry. 2015;206:275–282. [DOI] [PubMed] [Google Scholar]
- 67. Morgan VA, Morgan F, Galletly C, Valuri G, Shah S, Jablensky A. Sociodemographic, clinical and childhood correlates of adult violent victimisation in a large, national survey sample of people with psychotic disorders. Soc Psychiatry Psychiatr Epidemiol. 2016;51:269–279. [DOI] [PubMed] [Google Scholar]
- 68. Sartorius N, Jablensky A, Korten A, et al. Early manifestations and first-contact incidence of schizophrenia in different cultures. A preliminary report on the initial evaluation phase of the WHO Collaborative Study on determinants of outcome of severe mental disorders. Psychol Med. 1986;16:909–928. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.